DUBLIN--(BUSINESS WIRE)--The "Idiopathic Pulmonary Fibrosis - Pipeline Insights, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Idiopathic Pulmonary Fibrosis development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the Report
- The report provides a snapshot of the pipeline development for the Idiopathic Pulmonary Fibrosis
- The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Idiopathic Pulmonary Fibrosis
- The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Idiopathic Pulmonary Fibrosis
- The report also covers the dormant and discontinued pipeline projects related to Idiopathic Pulmonary Fibrosis
Reasons to Buy
- Establish comprehensive understanding of the pipeline activity across this Idiopathic Pulmonary Fibrosis to formulate effective R&D strategies
- Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
- Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Idiopathic Pulmonary Fibrosis therapeutics
- Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress
Companies Mentioned
- Asahi Kasei Pharma Corporation
- Celgene Corporation
- Hoffmann-La Roche
- Kadmon Corporation
- Merck & Co. Inc.
- Galapagos N.V.
- Beijing Tide Pharmaceutical Co. Ltd.
- Biogen Inc.
- Bristol-Myers Squibb
- Chong Kun Dang Pharmaceutical
- FibroGen
Topics Covered
1. Report Introduction
2. Idiopathic Pulmonary Fibrosis - Pipeline Insights
3. Pipeline Therapeutics
-
An Overview of Pipeline Products for Idiopathic Pulmonary Fibrosis
4. Comparative Analysis
5. Products in Clinical Stage
- Product Description
- Research and Development
- Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
8. Inactive Products
- Product Description
- Research and Development
-
Product Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4lqzrg/idiopathic?w=4
